Vitamin D signalling pathways in cancer: potential for anticancer therapeutics View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-09

AUTHORS

Kristin K. Deeb, Donald L. Trump, Candace S. Johnson

ABSTRACT

Key PointsEpidemiological studies point to a relationship between vitamin D deficiency and cancer risk.Alterations in vitamin D receptor expression, and in the synthesis (25-hydroxylase and 1α-hydroxylase) and catabolism (24-hydroxylase) of vitamin D metabolites are involved in the growth regulation of tumours; thus, compromising 1α,25(OH)2D3 (also known as calcitriol; the active metabolite of vitamin D signalling) sensitivity and 1α,25(OH)2D3 signalling.The antiproliferative effects of 1α,25(OH)2D3 have been demonstrated in various tumour types, as determined by preclinical trials.The anti-tumour effects of 1α,25(OH)2D3 involve mechanisms that are associated with G0/G1 arrest, differentiation, induction of apoptosis and modulating different signalling pathways in tumour cells, as well as inhibiting tumour angiogenesis.Glucocorticoids potentiate the anti-tumour effects of 1α,25(OH)2D3 and decrease 1α,25(OH)2D3-induced hypercalcemia. 1α,25(OH)2D3 also potentiates the anti-tumour effects of many chemotherapeutic agents such as platinum analogues, taxanes and DNA-intercalating agents.Given that the major vitamin D catabolizing enzyme, CYP24A1 (24-hydroxylase), is often amplified and overexpressed in tumour cells, agents that inhibit this enzyme can potentiate 1α,25(OH)2D3 anti-tumour effects.Preclinical data indicate that maximal anti-tumour effects are seen with pharmacological doses of 1α,25(OH)2D3, and can be safely achieved in animals using a high-dose, intermittent schedule of administration. Some clinical trial data indicates that 1α,25(OH)2D3 is well-tolerated in cancer patients within a proper dosing schedule.Data support the hypothesis that vitamin D compounds may have an important role in cancer therapy and prevention, and merit further investigation. More... »

PAGES

684-700

References to SciGraph publications

  • 2003. Analysis of the Vitamin D System in Cervical Carcinomas, Breast Cancer and Ovarian Cancer in VITAMIN D ANALOGS IN CANCER PREVENTION AND THERAPY
  • 2005-09-23. Expression of VDR and CYP24A1 mRNA in human tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2003-07-15. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma in BRITISH JOURNAL OF CANCER
  • 2004-04-12. Analysis of the vitamin D system in basal cell carcinomas (BCCs) in LABORATORY INVESTIGATION
  • 2002-12-28. Pharmacokinetics of high‐dose oral calcitriol: Results from a phase 1 trial of calcitriol and paclitaxel in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2004-08-09. Altered SMRT levels disrupt vitamin D3 receptor signalling in prostate cancer cells in ONCOGENE
  • 2005-07-11. 1α,25-Dihydroxyvitamin D3 regulates the expression of Id1 and Id2 genes and the angiogenic phenotype of human colon carcinoma cells in ONCOGENE
  • 1993-02. Two nuclear signalling pathways for vitamin D in NATURE
  • 2003-01. Nongenomic actions of steroid hormones in NATURE REVIEWS MOLECULAR CELL BIOLOGY
  • 2000-11. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland) in CANCER CAUSES & CONTROL
  • 1998-07. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer in BRITISH JOURNAL OF CANCER
  • 2006-10-26. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1997-08. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning in NATURE GENETICS
  • 2000-06. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene in NATURE GENETICS
  • 2001-05. The vitamin D3 analog, ILX-23-7553, enhances the response to Adriamycin and irradiation in MCF-7 breast tumor cells in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 1999-01. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo in BREAST CANCER RESEARCH AND TREATMENT
  • 2004-08-22. The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer in NATURE MEDICINE
  • 2002-02-26. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer in BRITISH JOURNAL OF CANCER
  • Journal

    TITLE

    Nature Reviews Cancer

    ISSUE

    9

    VOLUME

    7

    Related Patents

  • Methods For The Treatment Of Cancer Using Coenzyme Q10 Combination Therapies
  • Compositions For Treating Chronic Viral Infections
  • Methods Of Treatment Of Cancer By Continuous Infusion Of Coenzyme Q10
  • Methods For Treatment Of Oncological Disorders Using An Epimetabolic Shifter (Coenzyme Q10)
  • Combined Inhibition Of The Vitamin D Receptor And Poly(Adp) Ribose Polymerase (Parp) In The Treatment Of Cancer
  • 22-Haloacetoxy-Homopregnacalciferol Analogs And Their Uses
  • Methods For Treatment Of Oncological Disorders Using An Epimetabolic Shifter (Coenzyme Q10)
  • Compositions For Treating Chronic Viral Infections
  • Vitamin D Receptor Agonists To Treat Diseases Involving Cxcl12 Activity
  • Combined Inhibition Of The Vitamin D Receptor And Poly(Adp) Ribose Polymerase (Parp) In The Treatment Of Cancer
  • Vitamin D Analogues Of Pharmaceutical Interest
  • Methods For Treatment Of Oncological Disorders Using Epimetabolic Shifters, Multidimensional Intracellular Molecules, Or Environmental Influencers
  • Method Of Treating Or Preventing Tumors Of The Central Nervous System
  • Methods For Treatment Of Oncological Disorders Using An Epimetabolic Shifter (Coenzyme Q10)
  • 22-Haloacetoxy-Homopregnacalciferol Analogs And Their Uses
  • Combined Inhibition Of The Vitamin D Receptor And Dna Replication In The Treatment Of Cancer
  • Methods Of Treatment Of Cancer By Continuous Infusion Of Coenzyme Q10
  • Method Of Treating Or Preventing Tumors Of The Central Nervous System
  • Vitamin D Receptor Activators And Methods Of Making
  • Compositions And Methods For Characterizing And Treating Neoplasia
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/nrc2196

    DOI

    http://dx.doi.org/10.1038/nrc2196

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1021224284

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/17721433


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Anticarcinogenic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Apoptosis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Calcitriol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Synergism", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Glucocorticoids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hydroxycholecalciferols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Models, Biological", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoplasms", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Receptors, Calcitriol", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Signal Transduction", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Steroid Hydroxylases", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vitamin D", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vitamin D Deficiency", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Vitamin D3 24-Hydroxylase", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.240614.5", 
              "name": [
                "Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Deeb", 
            "givenName": "Kristin K.", 
            "id": "sg:person.01363321437.27", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363321437.27"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Departments of Pharmacology and Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.240614.5", 
              "name": [
                "Departments of Pharmacology and Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Trump", 
            "givenName": "Donald L.", 
            "id": "sg:person.0710021450.77", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA", 
              "id": "http://www.grid.ac/institutes/grid.240614.5", 
              "name": [
                "Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Johnson", 
            "givenName": "Candace S.", 
            "id": "sg:person.01032165723.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032165723.03"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/labinvest.3700096", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021211520", 
              "https://doi.org/10.1038/labinvest.3700096"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nm1095", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001975394", 
              "https://doi.org/10.1038/nm1095"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1067/mcp.2002.129305", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051587242", 
              "https://doi.org/10.1067/mcp.2002.129305"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-3-642-55580-0_17", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028286965", 
              "https://doi.org/10.1007/978-3-642-55580-0_17"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1208801", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030964758", 
              "https://doi.org/10.1038/sj.onc.1208801"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/75985", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012342798", 
              "https://doi.org/10.1038/75985"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-005-0059-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001043909", 
              "https://doi.org/10.1007/s00280-005-0059-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0897-391", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051287855", 
              "https://doi.org/10.1038/ng0897-391"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.1998.434", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023329108", 
              "https://doi.org/10.1038/bjc.1998.434"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006123819675", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043766444", 
              "https://doi.org/10.1023/a:1006123819675"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002800000251", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046762456", 
              "https://doi.org/10.1007/s002800000251"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6600162", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026341603", 
              "https://doi.org/10.1038/sj.bjc.6600162"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00280-006-0299-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002280301", 
              "https://doi.org/10.1007/s00280-006-0299-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.bjc.6601104", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006593873", 
              "https://doi.org/10.1038/sj.bjc.6601104"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrm1009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037773830", 
              "https://doi.org/10.1038/nrm1009"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1008923802001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030296825", 
              "https://doi.org/10.1023/a:1008923802001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.onc.1207772", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033026910", 
              "https://doi.org/10.1038/sj.onc.1207772"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/361657a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047914511", 
              "https://doi.org/10.1038/361657a0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2007-09", 
        "datePublishedReg": "2007-09-01", 
        "description": "Key PointsEpidemiological studies point to a relationship between vitamin D deficiency and cancer risk.Alterations in vitamin D receptor expression, and in the synthesis (25-hydroxylase and 1\u03b1-hydroxylase) and catabolism (24-hydroxylase) of vitamin D metabolites are involved in the growth regulation of tumours; thus, compromising 1\u03b1,25(OH)2D3 (also known as calcitriol; the active metabolite of vitamin D signalling) sensitivity and 1\u03b1,25(OH)2D3 signalling.The antiproliferative effects of 1\u03b1,25(OH)2D3 have been demonstrated in various tumour types, as determined by preclinical trials.The anti-tumour effects of 1\u03b1,25(OH)2D3 involve mechanisms that are associated with G0/G1 arrest, differentiation, induction of apoptosis and modulating different signalling pathways in tumour cells, as well as inhibiting tumour angiogenesis.Glucocorticoids potentiate the anti-tumour effects of 1\u03b1,25(OH)2D3 and decrease 1\u03b1,25(OH)2D3-induced hypercalcemia. 1\u03b1,25(OH)2D3 also potentiates the anti-tumour effects of many chemotherapeutic agents such as platinum analogues, taxanes and DNA-intercalating agents.Given that the major vitamin D catabolizing enzyme, CYP24A1 (24-hydroxylase), is often amplified and overexpressed in tumour cells, agents that inhibit this enzyme can potentiate 1\u03b1,25(OH)2D3 anti-tumour effects.Preclinical data indicate that maximal anti-tumour effects are seen with pharmacological doses of 1\u03b1,25(OH)2D3, and can be safely achieved in animals using a high-dose, intermittent schedule of administration. Some clinical trial data indicates that 1\u03b1,25(OH)2D3 is well-tolerated in cancer patients within a proper dosing schedule.Data support the hypothesis that vitamin D compounds may have an important role in cancer therapy and prevention, and merit further investigation.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/nrc2196", 
        "isAccessibleForFree": false, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.7143104", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1029716", 
            "issn": [
              "1474-175X", 
              "1474-1768"
            ], 
            "name": "Nature Reviews Cancer", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "9", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "7"
          }
        ], 
        "keywords": [
          "anti-tumor effects", 
          "vitamin D", 
          "maximal anti-tumor effect", 
          "vitamin D receptor expression", 
          "tumor cells", 
          "vitamin D deficiency", 
          "vitamin D metabolites", 
          "vitamin D compounds", 
          "clinical trial data", 
          "G0/G1 arrest", 
          "major vitamin D", 
          "D deficiency", 
          "dosing schedules", 
          "pharmacological doses", 
          "D metabolites", 
          "preclinical data", 
          "cancer patients", 
          "receptor expression", 
          "merit further investigation", 
          "cancer risk", 
          "tumor types", 
          "intermittent schedule", 
          "induction of apoptosis", 
          "trial data", 
          "preclinical trials", 
          "chemotherapeutic agents", 
          "tumor angiogenesis", 
          "antiproliferative effects", 
          "platinum analogues", 
          "D compounds", 
          "DNA-intercalating agents", 
          "different signaling pathways", 
          "cancer therapy", 
          "G1 arrest", 
          "signaling pathways", 
          "further investigation", 
          "anticancer therapeutics", 
          "growth regulation", 
          "agents", 
          "hypercalcemia", 
          "cells", 
          "patients", 
          "CYP24A1", 
          "glucocorticoids", 
          "therapy", 
          "tumors", 
          "taxanes", 
          "cancer", 
          "pathway", 
          "doses", 
          "administration", 
          "trials", 
          "prevention", 
          "important role", 
          "angiogenesis", 
          "effect", 
          "arrest", 
          "risk", 
          "schedule", 
          "apoptosis", 
          "therapeutics", 
          "alterations", 
          "induction", 
          "deficiency", 
          "animals", 
          "catabolism", 
          "metabolites", 
          "enzyme", 
          "expression", 
          "data", 
          "differentiation", 
          "study", 
          "role", 
          "regulation", 
          "sensitivity", 
          "hypothesis", 
          "mechanism", 
          "analogues", 
          "relationship", 
          "types", 
          "investigation", 
          "potential", 
          "compounds", 
          "synthesis"
        ], 
        "name": "Vitamin D signalling pathways in cancer: potential for anticancer therapeutics", 
        "pagination": "684-700", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1021224284"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/nrc2196"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "17721433"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/nrc2196", 
          "https://app.dimensions.ai/details/publication/pub.1021224284"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-12-01T06:26", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_435.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/nrc2196"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/nrc2196'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/nrc2196'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/nrc2196'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/nrc2196'


     

    This table displays all metadata directly associated to this object as RDF triples.

    299 TRIPLES      21 PREDICATES      144 URIs      118 LITERALS      23 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/nrc2196 schema:about N01cff46af750493da5b4921c3e78cd2e
    2 N1693bf8a8d6c484883a1711c7b2f710f
    3 N1b609c2c9d13497c9c2b8b677b77b886
    4 N328eaadf4c0b410ea7242db87453425a
    5 N4de565f959e6465489ce577bfa5042bd
    6 N5282c7aeb77c48aaa6ae6e7abdd1494a
    7 N63e1a43c1201488e9d457e911ff038da
    8 N7796998c04d749298bf600cddfeefd5a
    9 N7ba02f906cf346549e3949c3d8e49b11
    10 N8e001c489bb14c3796873dc28d6b58af
    11 Nb94804b00a344349825664a9342a6ae8
    12 Nbf6b4b39f8e8418e820199e6cde7b592
    13 Nbfe3e01c861c4316b156214fa5d6914f
    14 Nc04b2952196a4a8db9d1dd9c44adf3ce
    15 Ne505d3341c88457da8680c02a208b735
    16 Nf65250a53a4d44b5883e7d61514c8e93
    17 anzsrc-for:11
    18 anzsrc-for:1112
    19 schema:author N2c5db763dc114ef2aab7bd4e1cfa4708
    20 schema:citation sg:pub.10.1007/978-3-642-55580-0_17
    21 sg:pub.10.1007/s00280-005-0059-7
    22 sg:pub.10.1007/s00280-006-0299-1
    23 sg:pub.10.1007/s002800000251
    24 sg:pub.10.1023/a:1006123819675
    25 sg:pub.10.1023/a:1008923802001
    26 sg:pub.10.1038/361657a0
    27 sg:pub.10.1038/75985
    28 sg:pub.10.1038/bjc.1998.434
    29 sg:pub.10.1038/labinvest.3700096
    30 sg:pub.10.1038/ng0897-391
    31 sg:pub.10.1038/nm1095
    32 sg:pub.10.1038/nrm1009
    33 sg:pub.10.1038/sj.bjc.6600162
    34 sg:pub.10.1038/sj.bjc.6601104
    35 sg:pub.10.1038/sj.onc.1207772
    36 sg:pub.10.1038/sj.onc.1208801
    37 sg:pub.10.1067/mcp.2002.129305
    38 schema:datePublished 2007-09
    39 schema:datePublishedReg 2007-09-01
    40 schema:description Key PointsEpidemiological studies point to a relationship between vitamin D deficiency and cancer risk.Alterations in vitamin D receptor expression, and in the synthesis (25-hydroxylase and 1α-hydroxylase) and catabolism (24-hydroxylase) of vitamin D metabolites are involved in the growth regulation of tumours; thus, compromising 1α,25(OH)2D3 (also known as calcitriol; the active metabolite of vitamin D signalling) sensitivity and 1α,25(OH)2D3 signalling.The antiproliferative effects of 1α,25(OH)2D3 have been demonstrated in various tumour types, as determined by preclinical trials.The anti-tumour effects of 1α,25(OH)2D3 involve mechanisms that are associated with G0/G1 arrest, differentiation, induction of apoptosis and modulating different signalling pathways in tumour cells, as well as inhibiting tumour angiogenesis.Glucocorticoids potentiate the anti-tumour effects of 1α,25(OH)2D3 and decrease 1α,25(OH)2D3-induced hypercalcemia. 1α,25(OH)2D3 also potentiates the anti-tumour effects of many chemotherapeutic agents such as platinum analogues, taxanes and DNA-intercalating agents.Given that the major vitamin D catabolizing enzyme, CYP24A1 (24-hydroxylase), is often amplified and overexpressed in tumour cells, agents that inhibit this enzyme can potentiate 1α,25(OH)2D3 anti-tumour effects.Preclinical data indicate that maximal anti-tumour effects are seen with pharmacological doses of 1α,25(OH)2D3, and can be safely achieved in animals using a high-dose, intermittent schedule of administration. Some clinical trial data indicates that 1α,25(OH)2D3 is well-tolerated in cancer patients within a proper dosing schedule.Data support the hypothesis that vitamin D compounds may have an important role in cancer therapy and prevention, and merit further investigation.
    41 schema:genre article
    42 schema:isAccessibleForFree false
    43 schema:isPartOf N0fdbf44942494fc294f3456ae4b9e92b
    44 Nb6d49e85733b4ba7b67ecead558cbb0c
    45 sg:journal.1029716
    46 schema:keywords CYP24A1
    47 D compounds
    48 D deficiency
    49 D metabolites
    50 DNA-intercalating agents
    51 G0/G1 arrest
    52 G1 arrest
    53 administration
    54 agents
    55 alterations
    56 analogues
    57 angiogenesis
    58 animals
    59 anti-tumor effects
    60 anticancer therapeutics
    61 antiproliferative effects
    62 apoptosis
    63 arrest
    64 cancer
    65 cancer patients
    66 cancer risk
    67 cancer therapy
    68 catabolism
    69 cells
    70 chemotherapeutic agents
    71 clinical trial data
    72 compounds
    73 data
    74 deficiency
    75 different signaling pathways
    76 differentiation
    77 doses
    78 dosing schedules
    79 effect
    80 enzyme
    81 expression
    82 further investigation
    83 glucocorticoids
    84 growth regulation
    85 hypercalcemia
    86 hypothesis
    87 important role
    88 induction
    89 induction of apoptosis
    90 intermittent schedule
    91 investigation
    92 major vitamin D
    93 maximal anti-tumor effect
    94 mechanism
    95 merit further investigation
    96 metabolites
    97 pathway
    98 patients
    99 pharmacological doses
    100 platinum analogues
    101 potential
    102 preclinical data
    103 preclinical trials
    104 prevention
    105 receptor expression
    106 regulation
    107 relationship
    108 risk
    109 role
    110 schedule
    111 sensitivity
    112 signaling pathways
    113 study
    114 synthesis
    115 taxanes
    116 therapeutics
    117 therapy
    118 trial data
    119 trials
    120 tumor angiogenesis
    121 tumor cells
    122 tumor types
    123 tumors
    124 types
    125 vitamin D
    126 vitamin D compounds
    127 vitamin D deficiency
    128 vitamin D metabolites
    129 vitamin D receptor expression
    130 schema:name Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
    131 schema:pagination 684-700
    132 schema:productId N298b07a0f0d745a18ed96026bcf949ba
    133 Nd1ed3bf04c5845dda414fe48c8e01759
    134 Nd94d57a3a50b454784c90d7a01b019c5
    135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021224284
    136 https://doi.org/10.1038/nrc2196
    137 schema:sdDatePublished 2022-12-01T06:26
    138 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    139 schema:sdPublisher Ndcdeb1fb436c42329be4995f91c23eb6
    140 schema:url https://doi.org/10.1038/nrc2196
    141 sgo:license sg:explorer/license/
    142 sgo:sdDataset articles
    143 rdf:type schema:ScholarlyArticle
    144 N01cff46af750493da5b4921c3e78cd2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Glucocorticoids
    146 rdf:type schema:DefinedTerm
    147 N0fdbf44942494fc294f3456ae4b9e92b schema:issueNumber 9
    148 rdf:type schema:PublicationIssue
    149 N1693bf8a8d6c484883a1711c7b2f710f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Steroid Hydroxylases
    151 rdf:type schema:DefinedTerm
    152 N1b609c2c9d13497c9c2b8b677b77b886 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Receptors, Calcitriol
    154 rdf:type schema:DefinedTerm
    155 N298b07a0f0d745a18ed96026bcf949ba schema:name dimensions_id
    156 schema:value pub.1021224284
    157 rdf:type schema:PropertyValue
    158 N2c5db763dc114ef2aab7bd4e1cfa4708 rdf:first sg:person.01363321437.27
    159 rdf:rest N48d5ede7408b438fa78021f85d5a9bb9
    160 N328eaadf4c0b410ea7242db87453425a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Signal Transduction
    162 rdf:type schema:DefinedTerm
    163 N48d5ede7408b438fa78021f85d5a9bb9 rdf:first sg:person.0710021450.77
    164 rdf:rest Na5acff068c0742ae9a3edaa00be9f251
    165 N4de565f959e6465489ce577bfa5042bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Neoplasms
    167 rdf:type schema:DefinedTerm
    168 N5282c7aeb77c48aaa6ae6e7abdd1494a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Drug Synergism
    170 rdf:type schema:DefinedTerm
    171 N63e1a43c1201488e9d457e911ff038da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Antineoplastic Agents
    173 rdf:type schema:DefinedTerm
    174 N7796998c04d749298bf600cddfeefd5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Calcitriol
    176 rdf:type schema:DefinedTerm
    177 N7ba02f906cf346549e3949c3d8e49b11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    178 schema:name Vitamin D3 24-Hydroxylase
    179 rdf:type schema:DefinedTerm
    180 N8e001c489bb14c3796873dc28d6b58af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    181 schema:name Models, Biological
    182 rdf:type schema:DefinedTerm
    183 Na5acff068c0742ae9a3edaa00be9f251 rdf:first sg:person.01032165723.03
    184 rdf:rest rdf:nil
    185 Nb6d49e85733b4ba7b67ecead558cbb0c schema:volumeNumber 7
    186 rdf:type schema:PublicationVolume
    187 Nb94804b00a344349825664a9342a6ae8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Vitamin D Deficiency
    189 rdf:type schema:DefinedTerm
    190 Nbf6b4b39f8e8418e820199e6cde7b592 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Hydroxycholecalciferols
    192 rdf:type schema:DefinedTerm
    193 Nbfe3e01c861c4316b156214fa5d6914f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Vitamin D
    195 rdf:type schema:DefinedTerm
    196 Nc04b2952196a4a8db9d1dd9c44adf3ce schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    197 schema:name Anticarcinogenic Agents
    198 rdf:type schema:DefinedTerm
    199 Nd1ed3bf04c5845dda414fe48c8e01759 schema:name doi
    200 schema:value 10.1038/nrc2196
    201 rdf:type schema:PropertyValue
    202 Nd94d57a3a50b454784c90d7a01b019c5 schema:name pubmed_id
    203 schema:value 17721433
    204 rdf:type schema:PropertyValue
    205 Ndcdeb1fb436c42329be4995f91c23eb6 schema:name Springer Nature - SN SciGraph project
    206 rdf:type schema:Organization
    207 Ne505d3341c88457da8680c02a208b735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    208 schema:name Apoptosis
    209 rdf:type schema:DefinedTerm
    210 Nf65250a53a4d44b5883e7d61514c8e93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    211 schema:name Humans
    212 rdf:type schema:DefinedTerm
    213 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    214 schema:name Medical and Health Sciences
    215 rdf:type schema:DefinedTerm
    216 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    217 schema:name Oncology and Carcinogenesis
    218 rdf:type schema:DefinedTerm
    219 sg:grant.7143104 http://pending.schema.org/fundedItem sg:pub.10.1038/nrc2196
    220 rdf:type schema:MonetaryGrant
    221 sg:journal.1029716 schema:issn 1474-175X
    222 1474-1768
    223 schema:name Nature Reviews Cancer
    224 schema:publisher Springer Nature
    225 rdf:type schema:Periodical
    226 sg:person.01032165723.03 schema:affiliation grid-institutes:grid.240614.5
    227 schema:familyName Johnson
    228 schema:givenName Candace S.
    229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032165723.03
    230 rdf:type schema:Person
    231 sg:person.01363321437.27 schema:affiliation grid-institutes:grid.240614.5
    232 schema:familyName Deeb
    233 schema:givenName Kristin K.
    234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363321437.27
    235 rdf:type schema:Person
    236 sg:person.0710021450.77 schema:affiliation grid-institutes:grid.240614.5
    237 schema:familyName Trump
    238 schema:givenName Donald L.
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77
    240 rdf:type schema:Person
    241 sg:pub.10.1007/978-3-642-55580-0_17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028286965
    242 https://doi.org/10.1007/978-3-642-55580-0_17
    243 rdf:type schema:CreativeWork
    244 sg:pub.10.1007/s00280-005-0059-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001043909
    245 https://doi.org/10.1007/s00280-005-0059-7
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1007/s00280-006-0299-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002280301
    248 https://doi.org/10.1007/s00280-006-0299-1
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1007/s002800000251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046762456
    251 https://doi.org/10.1007/s002800000251
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1023/a:1006123819675 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043766444
    254 https://doi.org/10.1023/a:1006123819675
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1023/a:1008923802001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030296825
    257 https://doi.org/10.1023/a:1008923802001
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1038/361657a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047914511
    260 https://doi.org/10.1038/361657a0
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1038/75985 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012342798
    263 https://doi.org/10.1038/75985
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1038/bjc.1998.434 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023329108
    266 https://doi.org/10.1038/bjc.1998.434
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1038/labinvest.3700096 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021211520
    269 https://doi.org/10.1038/labinvest.3700096
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1038/ng0897-391 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051287855
    272 https://doi.org/10.1038/ng0897-391
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1038/nm1095 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001975394
    275 https://doi.org/10.1038/nm1095
    276 rdf:type schema:CreativeWork
    277 sg:pub.10.1038/nrm1009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037773830
    278 https://doi.org/10.1038/nrm1009
    279 rdf:type schema:CreativeWork
    280 sg:pub.10.1038/sj.bjc.6600162 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026341603
    281 https://doi.org/10.1038/sj.bjc.6600162
    282 rdf:type schema:CreativeWork
    283 sg:pub.10.1038/sj.bjc.6601104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006593873
    284 https://doi.org/10.1038/sj.bjc.6601104
    285 rdf:type schema:CreativeWork
    286 sg:pub.10.1038/sj.onc.1207772 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033026910
    287 https://doi.org/10.1038/sj.onc.1207772
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1038/sj.onc.1208801 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030964758
    290 https://doi.org/10.1038/sj.onc.1208801
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1067/mcp.2002.129305 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051587242
    293 https://doi.org/10.1067/mcp.2002.129305
    294 rdf:type schema:CreativeWork
    295 grid-institutes:grid.240614.5 schema:alternateName Departments of Pharmacology and Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    296 Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA
    297 schema:name Departments of Pharmacology and Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA
    298 Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA
    299 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...